Publication:
Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy with Hypercholesterolemia: A Randomized Controlled Trial

Simple item page
dc.contributor.authorPhanthaboon Wangpatharawaniten_US
dc.contributor.authorSomnuek Sungkanuparphen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-12-11T03:25:15Z
dc.date.accessioned2019-03-14T08:02:05Z
dc.date.available2018-12-11T03:25:15Z
dc.date.available2019-03-14T08:02:05Z
dc.date.issued2016-09-15en_US
dc.description.abstract© 2016 The Author. A randomized controlled trial was conducted among human immunodeficiency virus-infected patients receiving lopinavir/ritonavir-based regimens with hypercholesterolemia. Reduction of total cholesterol and low-density lipoprotein was significantly greater in patients who were randomized to the addition of atorvastatin compared with those who were switched from lopinavir/ritonavir to atazanavir/ritonavir.en_US
dc.identifier.citationClinical Infectious Diseases. Vol.63, No.6 (2016), 818-820en_US
dc.identifier.doi10.1093/cid/ciw395en_US
dc.identifier.issn15376591en_US
dc.identifier.issn10584838en_US
dc.identifier.other2-s2.0-84995467105en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/41150
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84995467105&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleSwitching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy with Hypercholesterolemia: A Randomized Controlled Trialen_US
dc.typeConference Paperen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84995467105&origin=inwarden_US

Files

Collections

Scopus 2016-2017